Recurrent salivary gland cancer

Current Treatment Options in Oncology

Volumn 13, Issue 1, 2012, Pages 58-70

  Gillespie, M Boyd ^a,c   Albergotti, W Greer ^a   Eisele, David W ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Recurrent salivary gland cancer; Recurrent salivary gland neoplasm; Salivary gland cancer; Salivary gland neoplasm; Salivary gland surgery; Salivary gland tumor

Indexed keywords

CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; KI 67 ANTIGEN; MITOXANTRONE; NAVELBINE; PACLITAXEL; PROTEIN P27; PROTEIN P53; TRASTUZUMAB;

ADENOCARCINOMA; ADENOID CYSTIC CARCINOMA; ADENOSQUAMOUS CARCINOMA; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; DISEASE FREE SURVIVAL; DISTANT METASTASIS; ECHOGRAPHY; FUSION GENE; GAMMA KNIFE RADIOSURGERY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; INTRAOPERATIVE RADIOTHERAPY; LONG TERM SURVIVAL; MANDIBLE RESECTION; MAXILLA RESECTION; MECT1 MAML2 GENE; MULTIMODALITY CANCER THERAPY; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PAROTIDECTOMY; PATIENT ASSESSMENT; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RECURRENT CANCER; RECURRENT SALIVARY GLAND CANCER; SALIVARY GLAND BIOPSY; SALIVARY GLAND CANCER; TUMOR VOLUME;

DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PALLIATIVE CARE; PROGNOSIS; RISK ASSESSMENT; SALIVARY GLAND NEOPLASMS;

EID: 84857657973     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-011-0174-0     Document Type: Article

References (33)

1. JP Jeannon F Calman M Gleeson, et al. 2009 Management of advanced parotid cancer: a systematic review Eur J Surg Oncol 35 908 915 19027261 10.1016/j.ejso.2008.10.009 Well-written meta-analysis of the available information on salivary gland cancer that covers the critical issues.
2. SG Surakanti M Agulnik 2008 Salivary gland malignancies: the role for chemotherapy and molecular targeted agents Semin Oncol 35 309 319 18544445 10.1053/j.seminoncol.2008.03.009 Excellent broad review of major chemotherapy classes that have been used to treat salivary cancer to date. (Pubitemid 351787699)
3. YYP Lee KT Wong AD King AT Ahuja 2008 Imaging of salivary gland tumors Eur J Radiol 66 419 436 18337041 10.1016/j.ejrad.2008.01.027 1:STN:280:DC%2BD1czmvVejsw%3D%3D
4. GV Shah 2002 MR imaging of the salivary glands Magn Reson Imaging Clin N Am 10 631 662 12685498 10.1016/S1064-9689(02)00015-6 (Pubitemid 36008969)
5. JW Keyes BA Harkness KM Greven, et al. 1994 Salivary gland tumors: pretherapy evaluation with PET Radiology 192 99 102 8208973 (Pubitemid 24191525)
6. www.nccn.org
7. EG Cohen SG Patel O Lin, et al. 2004 Fine-needle aspiration biopsy of salivary gland lesions in a selected patient population Arch Otolaryngol Head Neck Surg 130 773 778 15210562 10.1001/archotol.130.6.773 Important paper from Memorial Sloan Kettering on the role of FNA in the diagnosis of salivary tumors. (Pubitemid 38725055)
8. SM Kaszuba ME Zafereo DI Rosenthal, et al. 2007 Effect of initial treatment on disease outcome for patients with submandibular gland carcinoma Arch Otolaryngol Head Neck Surg 133 546 550 17576904 10.1001/archotol.133.6.546 (Pubitemid 46974883)
9. www.cancer.gov
10. A Skalova I Leivo K Von Boguslawsky E Saksela 1994 Cell proliferation correlates with prognosis in acinic cell carcinomas of salivary gland origin. Immunohistochemical study of 30 cases using the MIB 1 antibody in formalin-fixed paraffin sections J Pathol 173 13 21 7931834 10.1002/path.1711730104 1:STN:280:DyaK2M%2Fhslartg%3D%3D (Pubitemid 24182256)
11. H Luukkaa P Klemi I Leivo, et al. 2006 Prognostic significance of Ki-67 and p53 as tumor markers in salivary gland malignancies in Finland: an evaluation of 212 cases Acta Oncol 45 669 675 16938809 10.1080/02841860500543208
12. S Nordgard G Franzen M Boysen TB Halvorsen 1997 Ki-67 as a prognostic marker in adenoid cystic carcinoma assessed with the monoclonal antibody MIB1 in paraffin sections Laryngoscope 107 531 536 9111386 10.1097/00005537-199704000- 00019 1:STN:280:DyaK2s3msFCnuw%3D%3D (Pubitemid 27176065)
13. S Miyabe M Okabe H Nagatsuka, et al. 2009 Prognostic significance of p27Kip1, Ki-67, and CRTC1-MAML2 fusion transcript in mucoepidermoid carcinoma: a molecular and clinicopathologic study of 101 cases J Oral Maxillofac Surg 67 7 1432 1441 19531414 10.1016/j.joms.2009.03.021
14. J Hoyek-Gebeily E Nehme G Aftimos, et al. 2007 Prognostic significance of EGFR, p53 and E-cadherin in mucoepidermoid cancer of the salivary glands: a retrospective case series J Med Liban 55 83 88 17685120 (Pubitemid 47065890)
15. VJ Karja KJ Syrjanen AK Kurvinen SM Syrjanen 1997 Expression and mutations of p53 in salivary gland tumours J Oral Path Med 26 217 223 10.1111/j.1600-0714.1997.tb01227.x 1:STN:280:DyaK2szitFCmsA%3D%3D (Pubitemid 27324325)
16. T Kiyoshima K Shima I Kobayashi, et al. 2001 Expression of p53 tumor suppressor gene in adenoid cystic and mucoepidermoid carcinomas of the salivary glands Oral Oncol 37 315 317 11287288 10.1016/S1368-8375(00)00083-X 1:CAS:528:DC%2BD3MXisVWmt7c%3D (Pubitemid 32245858)
17. MD Williams DB Roberts MS Lies, et al. 2010 Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance Clin Can Res 16 2266 2274 10.1158/1078-0432.CCR-09-0238 1:CAS:528:DC%2BC3cXkslSmur0%3D The paper summarizes the main issues of why tumor markers may play an important role in the treatment of salivary malignancy in the future.
18. RR Seethala S Dacic K Cieply, et al. 2010 A reappraisal of the MECT1/MAML2 translocation in salivary mucoepidermoid carcinomas Am J Surg Pathol 34 1106 1121 20588178 10.1097/PAS.0b013e3181de3021
19. M Okabe S Miyabe H Nagatsuka, et al. 2006 MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma Clin Can Res 12 3902 3907 10.1158/1078-0432.CCR-05-2376 1:CAS:528:DC%2BD28XmsValt7s%3D (Pubitemid 44078073)
20. Y Okumura S Miyabe T Nakayama, et al. 2011 Impact of CRTC1/3-MAML2 fusions on histological classification and prognosis of mucoepidermoid carcinoma Histopathology 59 90 97 21668476 10.1111/j.1365-2559.2011.03890.x
21. O Ben-Izhak S Akrish S Gan RM Nagler 2009 p27 and salivary cancer Cancer Immunol Immunother 58 469 473 18663445 10.1007/s00262-008-0547-9 1:CAS:528:DC%2BD1MXitlCjuw%3D%3D
22. Terhaard CHJ. Postoperative and primary radiotherapy for salivary gland carcinomas: indications, techniques, and results. Int J Radiat Oncol Biol Phys. 2007; 69 Suppl: S52-S55. Excellent review of the role of radiotherapy for salivary cancer summarizing evidence concerning major issues.
23. D Alterio BA Jereczek-Fossa M Griseri, et al. 2011 Three-dimensional conformal postoperative radiotherapy in patients with parotid tumors: 10 years experience at the European Institute of Oncology Tumori 97 328 334 21789011
24. LD Locati P Bossi F Perrone, et al. 2009 Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study Oral Oncol 45 574 578 18804410 10.1016/j.oraloncology.2008.07.010 1:CAS:528:DC%2BD1MXnsl2gsrY%3D First large clinical trial investigating the role of novel small moleculae therapy for salivary cancer.
25. FV Mariano SD da Silva TC Chulan, et al. 2011 Clinicopathological factors are predictors of distant metastasis from major salivary gland carcinomas Int J Oral Maxillofac Surg 40 504 509 21251798 10.1016/j.ijom.2010.12.002 1:STN:280:DC%2BC3Mvls1GgtA%3D%3D
26. WH Westra JD Kronz DW Eisele 2002 The impact of second opinion surgical pathology on the practice of head and neck surgery: a decade experience at a large referral hospital Head Neck 24 684 693 12112543 10.1002/hed.10105 Large series stressing the importance of having an experienced head and neck pathologist when treating head and neck tumors. (Pubitemid 34734365)
27. K Kobayashi K Nakao M Yoshida, et al. 2009 Recurrent cancer of the parotid gland: how well does surgery work for locoregional failure? ORL J Otorhinolaryngol Relat Spec 71 239 243 19738397 10.1159/000236013
28. AW Pederson DJ Haraf EA Blair, et al. 2010 Chemoreirradiation for recurrent salivary malignancies Radiother Oncol 95 308 311 20385414 10.1016/j.radonc.2010.03.006 1:CAS:528:DC%2BC3cXmslChu78%3D Paper provides evidence of the relative safety of reirradiation protocols in recurrent salivary cancer
29. SA Laurie AL Ho MG Fury, et al. 2011 Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review Lancet Oncol 12 815 824 21147032 10.1016/S1470-2045(10)70245-X 1:CAS:528:DC%2BC3MXpslKhtLc%3D Excellent review of the role of chemotherapy in the management of advanced salivary cancer.
30. Papaspyrou G, Hoch S, Rinaldo A, et al. Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: a review. Head Neck 2011; 905-911.
31. SA Laurie LL Siu E Winquist, et al. 2010 A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer Cancer 116 362 368 19924794 10.1002/cncr.24745 1:CAS:528:DC%2BC3cXitFGit7o%3D
32. D Debaere V Vander Poorten S Nuyts, et al. 2011 Cyclophosphamide, doxorubicin, and cisplatin in advanced salivary gland cancer B-ENT 7 1 6 21563549 1:STN:280:DC%2BC3Mrgs1SksQ%3D%3D
33. R Haddad AD Colevas JF Krane, et al. 2003 Herceptin in patients with advanced or metastatic salivary gland carcinomas: a phase 2 study Oral Oncol 39 724 727 12907212 10.1016/S1368-8375(03)00097-6 1:CAS:528:DC%2BD3sXlvFymt74%3D (Pubitemid 36930120)